Interviews

A novel treatment combining chemotherapy and PRRT shows promising safety and efficacy for neuroendocrine tumors, with high response rates and ongoing trials.

Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT.

Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors.

Vivek Subbiah emphasizes tumor-agnostic therapies' potential to revolutionize cancer treatment by targeting genetic biomarkers, ensuring equitable access to precision medicine.

Experts discuss the importance of collaboration in improving surgical standards and treatment outcomes for neuroendocrine tumors through the CUTNETs initiative.

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid syndrome, following NCCN guidelines.

Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.

Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.

New trial results reveal ITM-11 significantly improves survival rates in GEP-NET patients, outperforming everolimus with better efficacy and safety profiles.

A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell carcinoma, despite higher toxicity risks.

A new study reveals that combining TAR-200 with cetrelimab significantly improves treatment outcomes for muscle-invasive bladder cancer patients.

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.

Explore the latest insights on somatostatin analogs, dose adjustments, and emerging treatments for managing carcinoid syndrome symptoms effectively.

Experts discuss the CUTNETs collaborative's efforts to enhance surgical care and standardize treatment for neuroendocrine tumors across multiple centers.

AI transforms healthcare by personalizing treatment plans and enhancing patient-provider communication, revolutionizing how we approach medical care.

Pierre Gholam, MD, associate professor of medicine at Case Western Reserve University School of Medicine, discusses his approach to recognizing and managing adverse events in patients receiving tyrosine kinase inhibitors for hepatocellular carcinoma.

Rising early-onset neuroendocrine tumors reveal unique challenges and disparities, highlighting the need for tailored care and research focused on younger patients.

John L. Marshall, MD, discusses the challenges faced by oncologists in managing colorectal cancer treatments seen during a Case-Based Roundtable event.

Dr Vishal A. Patel explores critical scenarios for using cemiplimab in treating high-risk cutaneous squamous cell carcinoma, enhancing patient outcomes through tailored strategies.

Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.

Emerging research highlights the rising incidence of early-onset neuroendocrine tumors, revealing unique challenges and symptom burdens in younger patients.

Dr Vishal A. Patel discusses innovative strategies for optimizing cemiplimab in treating high-risk cutaneous squamous cell carcinoma and enhancing patient outcomes.

Dr Patel highlights the groundbreaking C-POST trial results, showcasing cemiplimab's significant impact on disease-free survival in high-risk CSCC patients.

New research compares transarterial embolization and chemoembolization for treating neuroendocrine liver metastases, revealing unexpected safety differences.

Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved cemiplimab, addressing significant patient needs.

Dr Vishal A. Patel discusses the design and patient criteria for the pivotal C-POST trial evaluating adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.

A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant benefits for advanced prostate cancer treatment.

Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.

Justin Watts, MD, discusses key findings from a study of olutasidenib in patients with IDH1-mutated myelodysplastic syndrome.